Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Allakos Inc. (ALLK : NSDQ)
 
 • Company Description   
Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States.

Number of Employees: 192

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.00 Daily Weekly Monthly
20 Day Moving Average: 942,497 shares
Shares Outstanding: 54.78 (millions)
Market Capitalization: $164.33 (millions)
Beta: 0.96
52 Week High: $112.87
52 Week Low: $2.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.51% -22.86%
12 Week -46.33% -41.00%
Year To Date -69.36% -62.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
825 Industrial Road Suite 500
-
Redwood City,CA 94070
USA
ph: 650-597-5002
fax: -
ir@allakos.com http://www.allakos.com
 
 • General Corporate Information   
Officers
Robert Alexander - Chief Executive Officer and Director
Daniel Janney - Chairman of the Board
H. Baird Radford, III - Chief Financial Officer
Robert E. Andreatta - Director
Steven P. James - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 01671P100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 54.78
Most Recent Split Date: (:1)
Beta: 0.96
Market Capitalization: $164.33 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.61 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 32.54% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.63
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -246.15%
vs. Previous Quarter: -108.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -91.36
12/31/21 - -50.04
09/30/21 - -37.16
ROA
03/31/22 - -76.29
12/31/21 - -43.27
09/30/21 - -32.81
Current Ratio
03/31/22 - 6.87
12/31/21 - 11.22
09/30/21 - 13.08
Quick Ratio
03/31/22 - 6.87
12/31/21 - 11.22
09/30/21 - 13.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.74
12/31/21 - 8.20
09/30/21 - 9.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©